- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, b ...

Company Performance - Humacyte, Inc. (HUMA) experienced a daily increase of +1.18% to $1.71, outperforming the S&P 500's gain of 0.79% [1] - Over the past month, HUMA shares have risen by 4.97%, while the Medical sector and S&P 500 gained 3.99% and 1.27%, respectively [1] Earnings Projections - The upcoming earnings report for Humacyte is projected to show an EPS of -$0.17, reflecting a 48.48% increase compared to the same quarter last year [2] - Full-year Zacks Consensus Estimates forecast earnings of -$0.35 per share and revenue of $3.51 million, indicating year-over-year changes of +66.67% for earnings and 0% for revenue [2] Analyst Forecasts - Recent revisions to analyst forecasts for Humacyte are important as they reflect short-term business trends, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides a rating system that can help investors make informed decisions [4] Zacks Rank and Industry Position - Humacyte currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, which includes Humacyte, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering. Under the terms of the securities purchase agreement ...

Core Insights - Humacyte's shares experienced an 18% increase following the announcement of positive data from a humanitarian initiative utilizing their bio-engineered human tissue product, Symvess, for treating vascular trauma injuries [5] Company Summary - The initiative involved a total of 17 patients, indicating a focused application of Humacyte's technology in a real-world medical scenario [5]

Core Insights - Humacyte, Inc. announced positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine, with zero infections, amputations, or deaths reported in patients followed for up to 18 months [2][4][5] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [2][14] - The company aims to improve patient outcomes and reduce complications through innovative medical solutions [5][14] Product Details - Symvess is an acellular tissue engineered vessel indicated for use in adults with extremity arterial injury when urgent revascularization is needed and autologous vein graft is not feasible [6][14] - The product is designed to be immediately available off-the-shelf, which is critical in wartime situations [3][4] Clinical Results - In a study involving 17 patients with combat-related extremity vascular trauma, Symvess demonstrated a 30-day primary and secondary patency rate of 93.8% and a long-term patency rate of 87.1% [4] - At the 30-day follow-up, there were zero deaths, amputations, or infections, and these outcomes were sustained over the 18-month follow-up period [4][5] Expert Commentary - Dr. Oleksandr Sokolov emphasized the importance of biologic conduits like Symvess in advancing vascular trauma care, particularly in the context of modern warfare [3] - Dr. Laura Niklason highlighted the sustained benefits of Symvess for patients with severe combat injuries, reinforcing the product's potential in improving surgical outcomes [5] Regulatory Status - Humacyte's Biologics License Application for Symvess in the vascular trauma indication was approved by the FDA in December 2024 [14] - The product has received various designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for other vascular applications [15]

Company Performance - Humacyte, Inc. (HUMA) closed at $1.76, reflecting a +1.15% change from the previous day, outperforming the S&P 500's gain of 0.34% [1] - The stock has increased by 15.23% over the past month, significantly higher than the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54% [1] Earnings Forecast - Humacyte is expected to report an EPS of -$0.17, indicating a 48.48% improvement from the same quarter last year [2] - For the full year, analysts anticipate earnings of -$0.35 per share and revenue of $3.51 million, representing changes of +66.67% and 0% respectively from the previous year [2] Analyst Revisions - Recent revisions to analyst forecasts for Humacyte are important as they reflect short-term business trends, with positive revisions indicating optimism about the company's outlook [3] Zacks Rank - Humacyte currently holds a Zacks Rank of 4 (Sell), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Zacks Rank system has a strong track record, with 1 stocks delivering an average annual return of +25% since 1988 [5] Industry Overview - The Medical - Biomedical and Genetics industry, which includes Humacyte, has a Zacks Industry Rank of 80, placing it in the top 33% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [6]

– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowance of a U.S. ...

Company Performance - Humacyte, Inc. (HUMA) closed at $1.77, reflecting a -4.84% change from the previous day, underperforming compared to the S&P 500's daily gain of 0.44% [1] - The stock has increased by 17.72% over the past month, outperforming the Medical sector's gain of 1.25% and the S&P 500's gain of 4.03% [1] Earnings Estimates - The upcoming earnings per share (EPS) for Humacyte, Inc. are projected at -$0.17, indicating a 48.48% increase from the same quarter last year [2] - For the annual period, the Zacks Consensus Estimates predict an EPS of -$0.35 and revenue of $3.51 million, reflecting changes of +66.67% and 0% respectively from the previous year [2] Analyst Estimates and Rankings - Recent changes to analyst estimates for Humacyte, Inc. are important as they reflect short-term business trends and analyst optimism regarding profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Humacyte, Inc. at 4 (Sell) [5] - Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged [5] Industry Overview - Humacyte, Inc. operates within the Medical - Biomedical and Genetics industry, which currently holds a Zacks Industry Rank of 101, placing it in the top 41% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Insights - Humacyte, Inc. is advancing its coronary tissue engineered vessel (CTEV) into first-in-human studies for coronary artery bypass grafting (CABG) following promising preclinical results [1][4][5] Group 1: CTEV Development and Research - The CTEV has shown the ability to sustain blood flow, recellularize with host cells, and remodel to reduce size mismatch in a non-human primate model [1][3][7] - The study published in JACC indicates that all implanted CTEVs remained patent throughout a six-month follow-up, suggesting durability as a CABG conduit [3][7] - The CTEV is produced using the same bioengineering system as Humacyte's acellular tissue engineered vessel (ATEV) and is referred to as the small-diameter ATEV (sdATEV) [3] Group 2: Clinical Need and Market Opportunity - Cardiovascular disease is the leading cause of death globally, with coronary artery disease (CAD) affecting 1 in 20 adults aged 20 and older in the U.S. [2] - Current CABG procedures predominantly use saphenous vein grafts, which have a long-term patency failure rate of approximately 50% at 10 years [2] - There is a significant unmet clinical need for alternative conduits due to the limitations of available autologous veins or arteries [2] Group 3: Future Plans and Regulatory Pathway - Humacyte plans to file an Investigational New Drug (IND) application with the FDA in Q4 2025 to support the first-in-human study of the CTEV [4] - The company has reached agreements with the FDA based on a prior meeting, indicating a positive regulatory pathway [4][5]